Ryan & Maniskas, LLP Announces Investigation into the Proposed Merger of Dialysis Corporation of America, Inc.
14 Abril 2010 - 5:15PM
Business Wire
Ryan & Maniskas, LLP is investigating whether the directors
of Dialysis Corporation of America, Inc. ("Dialysis" or the
“Company”) (NASDAQ:DCAI) breached their fiduciary duties in
approving the proposed merger of the Company with U.S. Renal Care,
Inc. (“USRC”). USRC, through a subsidiary, will commence a tender
offer for all of the outstanding common shares of DCA for $11.25
per share in cash, followed by a merger to acquire all remaining
outstanding DCA shares at the same cash price paid in the tender
offer. The investigation concerns possible breaches of fiduciary
duty and other violations of law related to approval of the
transaction by Company’s board of directors.
If you own shares of Dialysis and would like to learn more about
these claims or if you wish to discuss these matters and have any
questions concerning this announcement or your rights, visit:
www.rmclasslaw.com/cases/dialysis, or contact Richard A. Maniskas,
Esquire toll-free: (877) 316-3218, or by e-mail:
rmaniskas@rmclasslaw.com. For more information about class action
cases in general, please visit our website: www.rmclasslaw.com.
Dialysis OF America (NASDAQ:DCAI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Dialysis OF America (NASDAQ:DCAI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Dialysis of America (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Ryan & Maniskas, LLP